Name

EonArk

Legal name

Shenzhen EonArk Technology Co., Ltd. (深圳无尽方舟科技有限公司)

Website

https://eonark.ai

Company type

Private

Founded year

2026

Operating status

Operating

Ownership category

akta.pro rank

Product category

Longevity Biotechnology Platform

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• AI drug discovery
• Longevity biotechnology
• Biological age testing
• Precision pet health
• Cross-species aging research

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Precision Health Products and Services: Precision health services for companion animals including methylation-based biological age testing, genetic risk assessment, health status monitoring, and long-term follow-up interventions. This serves as the early commercial entry point while generating real-world data for R&D.
2. Drug Development and Licensing: Long-term revenue stream from developing anti-aging drugs and interventions based on platform discoveries, targeting the longevity and lifespan extension market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

EonArk builds AI-driven longevity biotechnology products, centered on a proprietary Longevity Foundation Model and the H2P Cross-Species Transfer Learning Model that analyze cross-species, cross-organ, single-cell transcriptomics data to discover anti-aging intervention targets. The platform operates a Wet-Dry-Wet iterative discovery-validation loop and is paired with a Precision Health product line delivering methylation-based biological age testing, genetic risk assessment, and long-term health monitoring for companion animals, plus a Natural Small Molecule Screening Platform for drug discovery.

Product overview

EonArk operates as an AI-driven longevity biotechnology company with a unified platform architecture centered on the Longevity Foundation Model. The core offering comprises the EonArk AI Platform and H2P Cross-Species Transfer Learning Model, which process single-cell genomic data to discover intervention targets. The Precision Health product line serves as an early commercial entry point for companion animal health, providing methylation-based biological age testing and long-term health monitoring that feeds real-world data back into the R&D platform. The company also operates the Natural Small Molecule Screening Platform (deepnatural.top) for drug discovery, all unified by a wet-dry-wet iterative development approach.

Differentiator

Problem solved

Functional benefit

Brands

• Precision Health (精准健康): Precision health service focused on biological age measurement through methylation detection, genetic risk assessment, health status monitoring, and long-term follow-up for companion animals.
• H2P Cross-Species Transfer Learning Model

Products and services

• Longevity Foundation Model

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Gero: AI-aging research company deriving intervention targets from longitudinal and single-cell human data; strong overlap with EonArk's AI biology + longevity discovery thesis.
• BioAge Labs: AI-driven aging biology platform that uses ML on omics data to identify and validate intervention targets for age-related diseases; methodologically parallel to EonArk's H2P cross-species target identification approach.
• Insilico Medicine: AI-driven drug discovery platform with explicit longevity/anti-aging focus, combining deep generative models with wet-lab validation; closest direct analog to EonArk's Longevity Foundation Model + H2P stack.

Others

• Schrödinger: Public computational chemistry and molecular simulation platform serving pharma R&D; thematically adjacent as an AI/computational-biology infrastructure provider in the drug discovery ecosystem.

Broad incumbents

• Altos Labs: Multi-billion-dollar longevity biotech pursuing cellular rejuvenation across multiple modalities; competes for the same talent, scientific narrative, and pharma BD EonArk is targeting.
• Calico Life Sciences: Alphabet-owned longevity biotech with a broad portfolio approach to aging biology; a reference broad incumbent that anchors the anti-aging category in which EonArk competes.
• Recursion Pharmaceuticals: Established AI-driven drug discovery company using high-dimensional biological data and automated wet labs; thematically similar AI-bio convergence but with a broader therapeutic focus than EonArk.

Emerging players

• Loyal for Dogs: Companion animal longevity pharma developing drugs to extend healthy lifespan in dogs; parallels EonArk's pet health commercial entry and the translational animal-to-human longevity thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EonArk